Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Stratus Therapeutics | 2025 | Series A | $50.0M | Cambridge |
| Aer Therapeutics | 2025 | Series Unknown | $5.0M | Raleigh |
| Helicore Biopharma | 2025 | Series A | $65.0M | San Mateo |
| 89bio | 2025 | Post Ipo Equity | $287.5M | San Francisco |
| Third Harmonic Bio | 2025 | Post Ipo Equity | $3.9M | Cambridge |
| Aerin Medical | 2025 | Undisclosed | $32.5M | Mountain View |
| Verdiva Bio | 2025 | Series A | $411.0M | London |
| Ottimo Pharma | 2024 | Series A | $140.0M | Sandwich |
| SiteOne Therapeutics | 2024 | Series C | $100.0M | South San Francisco |
| Janux Therapeutics | 2024 | Post Ipo Equity | $350.0M | La Jolla |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | Stratus Therapeutics | Series A | $50.0M | Cambridge, United States |
| 127 | Aer Therapeutics | Series Unknown | $5.0M | Raleigh, United States |
| 128 | Helicore Biopharma | Series A | $65.0M | San Mateo, United States |
| 129 | 89bio | Post Ipo Equity | $287.5M | San Francisco, United States |
| 130 | Third Harmonic Bio | Post Ipo Equity | $3.9M | Cambridge, United States |
| 131 | Aerin Medical | Undisclosed | $32.5M | Mountain View, United States |
| 132 | Verdiva Bio | Series A | $411.0M | London, United Kingdom |
| 133 | Ottimo Pharma | Series A | $140.0M | Sandwich, United Kingdom |
| 134 | SiteOne Therapeutics | Series C | $100.0M | South San Francisco, United States |
| 135 | Janux Therapeutics | Post Ipo Equity | $350.0M | La Jolla, United States |
Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.
Helicore Biopharma is a biopharmaceutical company that discovers and develops novel weight-loss therapeutics.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
ScPharmaceuticals is a biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics.
Brenig Therapeutics develops therapies for neurodegenerative disorders.
Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 12 different industry categories.
Among tracked funding rounds, Verdiva Bio received $411.0M in a Series A round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include Stratus Therapeutics, Aer Therapeutics, Helicore Biopharma, 89bio, Third Harmonic Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors